Alzheimer's Breakthrough: Copper Drug Repairs Brain's Waste System

Scientists at Monash University have identified a copper-based compound, Cu(ATSM), as a potential new treatment for Alzheimer's disease. Laboratory studies demonstrated that this drug significantly reduces toxic amyloid-beta proteins, which are hallmarks of Alzheimer's, and concurrently improves spatial memory. The treatment targets a breakdown in the brain's waste-clearance system, specifically by increasing the number and efficiency of P-glycoprotein (P-gp) pumps. This enhancement helps restore the blood-brain barrier's function, allowing for more effective removal of harmful waste products from the brain.

The research showed that Cu(ATSM) increased P-gp pumps by 24.1 percent in an Alzheimer's model. Over 56 days, this intervention led to a 42 percent reduction in amyloid-beta and a nearly 44 percent improvement in spatial learning. The compound's prior safety testing in clinical trials for Parkinson's and ALS could expedite its evaluation for early symptomatic Alzheimer's disease.

While promising, further research is needed to fully understand how amyloid-beta is cleared and if Cu(ATSM) also boosts microglial activity. Experts emphasize the importance of moving from preclinical findings to human trials to assess safety, efficacy, and clinical benefit. The study offers hope for future Alzheimer's therapies by targeting the brain's intrinsic cleaning mechanisms.